Karen focuses on therapeutic investments and on the identification and evaluation of investment opportunities.
Karen serves on the board of Galecto, Xeltis, Vivet Therapeutics, AELIX Therapeutics and Minoryx Therapeutics. Formerly, she was board member at Cardoz and observer on the board of Kala Pharmaceuticals.
Karen started her career as a consultant in McKinsey & Company’s Global Healthcare Practice. She went on to become a business development professional, first at Ingenium Pharmaceuticals in Munich, Germany, then at GLYCART in Zurich, Switzerland, where she worked together with Ysios colleague Joël Jean-Mairet. After the sale of GLYCART to F. Hoffmann-La Roche in 2005, Karen worked at Roche where she was responsible for business development and alliance management in the areas of drug discovery technologies, preclinical oncology and viral diseases. From 2007 until 2014, Karen managed an independent consultancy firm providing advice and hands-on support to various biotechnology companies in business development and strategy, while supporting Ysios as a venture partner.
Karen holds a master’s degree in Molecular Biology and a PhD in Cell Biology, both from the University of Konstanz, Germany.